This study is a cross disciplinary project with partners from DTU Food, DTU Bioinformatics and DTU Chemistry as well as collaborators from DTU Vet. Additionally, the project is conducted in collaboration an startup company partner Idun genomics IVS. The project is funded by the DTU PoC Fund.
We have identified a novel drug target for the treatment of inflammatory bowel diseases (IBD).
IBD are autoimmune and chronic diseases involving relapsing inflammation of the gastrointestinal tract (GIT). The two major types of IBD are Crohn’s disease (CD), involving inflammation in any part of the GIT, and ulcerative colitis (UC), where inflammation is limited to the colon. IBD is believed to result from continuous inappropriate inflammation in response to commensal microbes in susceptible individuals, but the etiology and pathogenesis of IBD is poorly understood. Current treatment of IBD includes aminosalicylates, corticosteroids, immune modifiers or anti-tumor necrosis factor (anti-TNF) agents, but a great number of patients are still unresponsive to treatment or become unresponsive over time.
The aim of this project is to investigate novel, proprietary compounds for their effect on a newly identified IBD drug target. You will learn about working with human cell lines and in a mammalian cell lab. The different technics that you will learn are ELISA, cAMP assay, western blotting and qRT-PCR. Additionally, other molecular and cell biological methods will be used. As part of the project, the best candidate molecules will be selected for testing in an in vivo animal model for IBD. We are looking for an ambitious and goal oriented student with a flair for laboratory work that wants to join a cross disciplinary and energetic team.
If you will like to hear more about the team and the project please contact: